Equities Analysts Issue Forecasts for Harrow Q1 Earnings

Key Points

• Harrow, Inc. is expected to earn $0.13 per share in Q1 2026 according to HC Wainwright, which maintains a "Buy" rating and a $64.00 target price for the stock.
• The company reported Q2 earnings with $0.24 EPS, significantly exceeding analyst estimates by $0.23, despite a slight miss in revenue expectations.
• Recent institutional investments saw notable increases, including Voya Investment Management growing its stake by 4,035.5%, highlighting strong interest in Harrow from large investors.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Harrow in a research note issued on Wednesday, August 13th. HC Wainwright analyst Y. Chen expects that the company will earn $0.13 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $64.00 target price on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow's Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.24 EPS and Q4 2026 earnings at $0.34 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.23. The business had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%.

HROW has been the topic of a number of other reports. BTIG Research boosted their price target on shares of Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research note on Thursday. Cantor Fitzgerald initiated coverage on shares of Harrow in a research note on Friday, July 11th. They issued an "overweight" rating and a $76.00 price target on the stock. Finally, William Blair initiated coverage on shares of Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $64.67.

Harrow Trading Up 2.5%

Shares of Harrow stock traded up $0.91 on Thursday, reaching $37.41. The company had a trading volume of 141,351 shares, compared to its average volume of 473,235. The firm's 50 day moving average price is $32.77 and its two-hundred day moving average price is $28.81. The firm has a market cap of $1.38 billion, a PE ratio of -149.06 and a beta of 0.41. Harrow has a 52-week low of $20.85 and a 52-week high of $59.23. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.85 and a current ratio of 0.62.

Institutional Investors Weigh In On Harrow

Several large investors have recently added to or reduced their stakes in HROW. Braidwell LP increased its stake in Harrow by 106.3% during the 4th quarter. Braidwell LP now owns 907,039 shares of the company's stock worth $30,431,000 after buying an additional 467,401 shares during the period. Voya Investment Management LLC grew its holdings in Harrow by 4,035.5% during the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock worth $10,147,000 after acquiring an additional 372,237 shares in the last quarter. Diametric Capital LP acquired a new position in Harrow during the 2nd quarter worth approximately $4,748,000. Divisadero Street Capital Management LP acquired a new position in Harrow during the 2nd quarter worth approximately $4,293,000. Finally, Invesco Ltd. grew its holdings in Harrow by 967.6% during the 2nd quarter. Invesco Ltd. now owns 150,948 shares of the company's stock worth $4,610,000 after acquiring an additional 136,809 shares in the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.